If you’re like most people, you don’t pay a lot of attention to serious health issues unless they affect you or a loved one. Alzheimer’s fell into that category for me until a dear neighbor developed the disease and I saw, first-hand, the toll it took not only on him but his devoted partner and caregiver.
That’s why I found this news below, shared by the Alzheimer’s Association Cleveland Area Chapter, especially interesting. It lists the five things researchers have learned about Alzheimer’s in 2024. The news is illuminating and hopeful.
Marie Elium, editor
Nearly 7 million Americans are living with Alzheimer’s dementia, including 236,200 in Ohio. A total of 414,000 Ohio caregivers provide 624 million hours of unpaid care each year, valued at more than $11.4 billion. To learn more about Alzheimer’s or other dementia and to access free support and resources, visit alz.org/cleveland or call the Cleveland chapter at 216.342.5556.
Here are the top five discoveries from 2024:
FDA APPROVES THIRD DRUG THAT SLOWS THE COURSE OF ALZHEIMER’S DISEASE
2024 saw a new drug enter the dementia landscape, as the U.S. Food and Drug Administration (FDA) approved Kisunla (donanemab) in July. This was the third new approval since 2021.
Kisunla, which is made by Eli Lilly, is designed to “slow progression and change the underlying course of the disease,” according to the Association’s press release. The once-monthly injection is intended for adults with early symptomatic Alzheimer’s disease.
This is the first medication to target amyloid plaques – the proteins that build up in the brains of Alzheimer’s patients, often impairing memory and cognitive function – with evidence to support stopping therapy when amyloid plaques are removed, a company release stated.
“This is real progress,” says Alzheimer’s Association President and CEO Dr. Joanne Pike. “[This FDA] approval allows people more options and greater opportunity to have more time. Having multiple treatment options is the kind of advancement we’ve all been waiting for.”
BLOOD TESTS COULD IMPROVE SPEED AND ACCURACY OF DIAGNOSIS
Research this year has helped move Alzheimer’s blood tests closer to being used in physicians’ offices.
Studies have shown that blood tests can achieve a higher accuracy of diagnosis, which could help fast-track patients’ access to clinical trials and treatments, according to the Alzheimer’s Association.
“Blood tests for Alzheimer’s are demonstrating in research that they could significantly improve a clinician’s accuracy and confidence, provide greater accessibility and a reason for more communication,” Dr. Pike says.
In one study reported this year, a specific blood test was around 90% accurate in identifying Alzheimer’s in patients with cognitive symptoms seen in primary care and at specialized memory care clinics, per the Association.
INDIVIDUALS AND CAREGIVERS WANT MORE SUPPORT POST-DIAGNOSIS
People who are newly diagnosed with Alzheimer’s and their caregivers need more support in navigating the healthcare system. That’s according to a 2024 Alzheimer’s Association survey, which found that 97% of dementia caregivers expressed a desire for those support systems.
A majority of dementia caregivers (70%) also noted that “coordination of care is stressful.”
To help address this, the Centers for Medicare & Medicaid Services in July 2024 launched an eight-year pilot program in dementia care management, called the Guiding an Improved Dementia Experience (GUIDE) model.
The program aims to work with health care systems to provide supportive services to people living with dementia and their caregivers, with a focus on helping patients remain in their homes and communities, according to the Alzheimer’s Association.
WILDFIRE SMOKE RAISES RISK OF DEMENTIA MORE THAN OTHER AIR POLLUTION
Air pollution has been linked to an increased risk of dementia, according to 2024 research. The 10-year study, which was presented during the Alzheimer’s Association International Conference in Philadelphia in July, found that wildfire smoke can be “particularly hazardous” for brain health.
The research included more than 1.2 million people in southern California, an area that experiences frequent wildfire activity.
Air pollution produced by wildfires could be more hazardous to health because it is produced at higher temperatures, contains a greater concentration of toxic chemicals, and is smaller in diameter than other sources, the Alzheimer’s Association stated.
SCIENTISTS DEFINE ALZHEIMER’S BY THE PHYSICAL CHANGES IN THE BRAIN
In June 2024, scientists and clinicians published research that showed physical changes that happen in the brain due to Alzheimer’s disease.
“Defining diseases by their biology has long been standard in many areas of medicine — including cancer, heart disease and diabetes,” the Alzheimer’s Association wrote. “The new publication defines Alzheimer’s as a biological process that begins with brain changes before people exhibit memory and thinking problems.”
These brain changes were found to come ahead of the typical outward symptoms, such as memory loss, confusion, disorientation and trouble with planning or organizing.
Additional research and support resources from the Alzheimer’s Association can be found at alz.org.
Nearly 7 million Americans are living with Alzheimer’s dementia, including 236,200 in Ohio. A total of 414,000 Ohio caregivers provide 624 million hours of unpaid care each year, valued at more than $11.4 billion. To learn more about Alzheimer’s or other dementia and to access free support and resources, visit alz.org/cleveland or call the Cleveland chapter at 216.342.5556.
